Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARE followed by gemcitabine + cisplatin + durvalumab for unresectable intrahepatic cholangiocarcinoma
2022-003787-24Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2023
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Overall response rate. Started Jan 2023; status: active.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2022-003787-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003787-24.